NSNamita Sood

Namita Sood

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Namita Sood has a total of 14 co-authors. Here are the top co-authors by number of shared publications:

  • Aneesa M Das

    Sleep Institute of Augusta, 3685 Wheeler Road, Suite 101, Augusta, GA 30909, USA

    1 shared publication
  • Cynthia Magro

    1 shared publication
  • I P Neuringer

    Lung Transplantation Program and Cystic Fibrosis Research and Treatment Center, Division of Pulmonary Diseases and Critical Care Medicine, University of North Carolina at Chapel Hill, NC, USA

    1 shared publication
  • Katherine Hodgin

    University of Colorado Health Sciences Center, 4200 East 9th Avenue, Mailbox C272, Denver, CO 80262, USA

    1 shared publication
  • L Chang

    Lung Transplantation Program and Cystic Fibrosis Research and Treatment Center, Division of Pulmonary Diseases and Critical Care Medicine, University of North Carolina at Chapel Hill, NC, USA

    1 shared publication
  • L J Paradowski

    Lung Transplantation Program and Cystic Fibrosis Research and Treatment Center, Division of Pulmonary Diseases and Critical Care Medicine, University of North Carolina at Chapel Hill, NC, USA

    1 shared publication

Latest Publications

  • Managing an acutely ill patient with pulmonary arterial hypertension

    by Namita Sood

    Pulmonary arterial hypertension (PAH) is a progressive disease characterized by a vasculopathy that results in sustained elevation of pulmonary artery pressures, which ultimately leads to right ventricular failure (RVF) and death. Several advances have been made in the treatment of PAH, but it remains a major cause of morbidity and mortality. Managing an acutely ill patient with PAH is especially challenging. The mechanisms of RVF are incompletely understood; these patients do not tolerate fluid shifts well and there are no controlled trials to assess superiority of a certain approach. This article outlines an approach based on current understanding of RVF in PAH and recommends an approach based on the pathophysiology, current evidence and experience.


  • Open Access

    Development of a triage protocol for patients presenting with gastrointestinal hemorrhage: a prospective cohort study

    by Aneesa M Das, Namita Sood, Katherine Hodgin, Lydia Chang, Shannon S Carson

    Introduction: Many patients presenting with acute gastrointestinal hemorrhage (GIH) are admitted to the intensive care unit (ICU) for monitoring. A simple triage protocol based upon validated risk factors could decrease ICU utilization. Methods: Records of 188 patients admitted with GIH from the emergency department (ED) were reviewed for BLEED criteria (visualized red blood, systolic blood pressure below 100 mm Hg, elevated prothrombin time [PT], erratic mental status, and unstable comorbid disease) and complication within the first 24 hours of admission. Variables associated with early complication were reassessed in 132 patients prospectively enrolled as a validation cohort. A triage model was developed using significant predictors. Results: We studied 188 patients in the development set and 132 in the validation set. Red blood (relative risk [RR] 4.53, 95% confidence interval [CI] 2.04, 10.07) and elevated PT (RR 3.27, 95% CI 1.53, 7.01) were significantly associated with complication in the development set. In the validation cohort, the combination of red blood or unstable comorbidity had a sensitivity of 0.73, a specificity of 0.55, a positive predictive value of 0.24, and a negative predictive value of 0.91 for complication within 24 hours. In simulation studies, a triage model using these variables could reduce ICU admissions without increasing the number of complications. Conclusion: Patients presenting to the ED with GIH who have no evidence of ongoing bleeding or unstable comorbidities are at low risk for complication during hospital admission. A triage model based on these variables should be tested prospectively to optimize critical care resource utilization in this common condition.


  • Open Access

    Pulmonary hypertension in Hodgkin's disease

    by Matthew Exline, Cynthia Magro, Thomas Lin, Namita Sood

    Pulmonary function tests showed mild restrictive disease, reduced diffusion capacity and desaturation during a 6-min walk. Echocardiogram showed a severely dilated and hypokinetic right ventricle. Right heart catheterisation showed pulmonary artery pressure 79/38 mm Hg (mean 46 mm Hg), cardiac output 6.7 l/min and cardiac index 3.7 l/min/m2. There was no significant response to inhaled nitric oxide at 20 ppm.


  • Open Access

    Non-tuberculous mycobacteria in end stage cystic fibrosis: implications for lung transplantation

    by W Chalermskulrat, N Sood, I P Neuringer, T M Hecker, L Chang, M P Rivera, L J Paradowski, R M Aris

    Background: WC and NS contributed equally. Non-tuberculous mycobacteria (NTM) frequently colonise patients with end stage cystic fibrosis (CF), but its impact on the course of the disease following lung transplantation is unknown. Methods: Lung transplant recipients with CF who underwent lung transplantation at our institution between January 1990 and May 2003 (n = 146) and CF patients awaiting lung transplantation in May 2003 (n = 31) were studied retrospectively. Results: The prevalence rate of NTM isolated from respiratory cultures in patients with end stage CF referred for lung transplantation was 19.7%, compared with a prevalence rate of 13.7% for NTM isolates in CF lung transplant recipients. The overall prevalence of invasive NTM disease after lung transplantation was low (3.4%) and was predicted most strongly by pre-transplant NTM isolation (p = 0.001, Fisher’s exact test, odds ratio (OR) 6.13, 95% CI 3.2 to 11.4). This association was restricted to Mycobacterium abscessus (p = 0.005, Fisher’s exact test, OR 7.45, 95% CI 2.9 to 16.9). While NTM disease caused significant morbidity in a small number of patients after transplantation, it was successfully treated and did not influence the post-transplant course of the disease. Conclusion: The isolation of NTM before transplantation in CF patients should not be an exclusion criterion for lung transplantation, but it may alert the clinician to patients at risk of recurrence following transplantation.